← Leaderboards
Michal Oskar Nowicki
Brigham And Women'S Hospital
$662,405
Attributed
$662,405
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $132.5K · FY2019–23$200K$150K$100K$50K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$662,405 · 1
By mechanism
R50$662,405 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Kenneth M Kaye$21,944,697
- Frederick C. Wang$16,331,006
- Kullervo Hynynen$20,293,002
- Daniel R Kuritzkes$313,891,104
- Keith L Ligon$15,402,631
Others in their field
Other Emerging Leaders on “In Vitro Assay”
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,503,168
- Lynn Briscoe · Leidos Biomedical Research, Inc.$95,408,471
- Leonard Freedmand · Leidos Biomedical Research, Inc.$55,464,221
- John Damon Chodera · Sloan-Kettering Inst Can Research$35,477,884
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$22,044,232
Research focus
In Vitro AssayAnimal Cancer ModelAnimal ModelBrain NeoplasmsBiochemistryCellular BiologyClinical TrialsBiologyCytomegalovirusCytotoxicCellsDiagnosisFundingGene Therapy AgentGlioblastomaHerpesviridaeHospitalsCollaborationsImmune Checkpoint BlockadeImmunosuppressionInnovationInnovative TechnologiesInvadedLaboratories
Grant awards (5)
Innovative approaches for the advancement of glioblastoma therapies$132,481
R50 · FY2023 · CA · contact PI
Innovative approaches for the advancement of glioblastoma therapies$132,481
R50 · FY2022 · CA · contact PI
Innovative approaches for the advancement of glioblastoma therapies$132,481
R50 · FY2021 · CA · contact PI
Innovative approaches for the advancement of glioblastoma therapies$132,481
R50 · FY2020 · CA · contact PI
Innovative approaches for the advancement of glioblastoma therapies$132,481
R50 · FY2019 · CA · contact PI